School of Medicine | University of Colorado



Victor M. Villalobos, M.D., Ph.D.University of Colorado Anschutz Medical Campus1665 Aurora Court Anschutz Cancer Pavilion Room 5329, mail stop F704Aurora, COPROFESSIONAL/ACADEMIC APPOINTMENTS9/15/2014 – currentAssistant Professor of MedicineDivision of Medical OncologyUniversity of Colorado Anschutz Medical Campus9/15/2014 – current Director, Sarcoma Medical Oncology University of Colorado Anschutz Medical Campus5/1/2015 – current Director, T3 (Target-based Therapeutics Team), a multi-disease clinical research team dedicated to basket cohort, target based and supportive oncology trials.University of Colorado Anschutz Medical Campus7/1/2013 – 9/3/2014 Instructor of MedicineSarcoma, unknown primary cancers, and rare tumors clinic. Division of Medical OncologyStanford University Medical CenterTRAINING 7/1/2008 – 6/30/2010 Internal Medicine ResidencyStanford University Medical Center7/1/2010 – 6/30/2013Fellowship in Medical OncologyStanford University Medical CenterEDUCATION1995 – 1999 Baylor University; Waco, TX Bachelor of Science, Biochemistry, Emphasis on Organic SynthesisResearch Advisor: Kevin Pinney, Ph.D. 1999 – 2008 Washington University School of Medicine; St. Louis, MODoctor of Medicine, May 2008Doctor of Philosophy in Chemical Biology, February 2007Research Advisor: David Piwnica-Worms, M.D., Ph.D. Thesis: “Development and Characterization of Novel Optical Biosensors for Real-Time Interrogation of Signal Transduction Cascades in Live Cells.” 2012 Stanford University; Stanford, CAIntensive Course in Clinical Research: Study Design and PerformanceStanford Center for Clinical and Translational Education and Research BOARD CERTIFICATION AND LICENSING5/2008Physician and Surgeon License in California Lic# CA-A1093968/16/2012Board certification in Internal Medicine (ABIM)11/13/2013Board certification in Medical Oncology (ABIM)8/2014Physician License in ColoradoLic # DR.0054330 PROFESSIONAL SOCIETIES2001 – 2010 Society for Molecular Imaging 2010 – presentAmerican Society of Clinical Oncology 2012 – present American College of Physicians 2012 – current Member Sarcoma Alliance through Research and Collaboration (SARC)2013 – present Connective Tissue Oncology Society 2014 – present SWOG 2015 – present Rocky Mountain Oncology SocietyPROFESSIONAL APPOINTMENTS & HONORS2011 – 2014 ASCO University Committee 2011 – 2014 ASCO Professional Development Committee 2011 – 2014ASCO Oncology Training Programs Subcommittee 2011 – 2014 ASCO Integrated Media and Technology Committee 2013 ASCO Excellence in Teaching Award Selection Committee2012 – 2014 Planning Committee: Stanford Multidisciplinary Management of Cancers2014 – currentAssociate Editor – ASCO University Editorial Board2014 – current Steering Committee Member – University of Colorado Denver Molecular Tumor Board2014 – current Member, SWOG Early Therapeutics and Rare Cancers Committee 2014 – 2015 Member, SWOG Sarcoma Survivorship Subcommittee2015 – current NCCN Bone Cancer Guideline Panel Member2015 – currentMember, Intermountain Cancer Center Molecular Tumor Board2015 – current Study Section and Grant Review - FDA Orphan Products Development2016 – currentRocky Mountain Oncology Society Board Member2016 – current Study Section and Grant Review - FDA Orphan Products Development - Orphan Products Natural History Grants programJOURNAL PEER-REVIEWER2014 – current ASCO University Editorial Board2016Journal of Oncology Practice 2016 Scientific Reports2016 Case Reports in Oncological Medicine2016 JCO Precision Medicine2016 Oncology Board Review ManualHONORS AND AWARDS2002 – 2003 Nuclear Medicine Training Grant, Department of Energy2013 – 2015 NIH Loan Repayment Program Award 2013-20152015 – 2017Hope Foundation – SWOG Rare Tumors FellowCLINICAL EXPERTISE2014 – currentUniversity of Colorado Hospital – Anschutz Medical CampusDirector, Sarcoma Medical Oncology Mentor: Anthony Elias, MDEarly phase developmental therapeuticsMentors: Gail Eckhardt, MD; Wells Messersmith, MD2008 – 2014 Stanford University Hospitals and Clinics, Stanford, CA. Soft Tissue and Bone SarcomaMentors: Kristen Ganjoo, MD; Sant Chawla, MD, FRACPCarcinoma of unknown primary, ovarian, and other rare cancersEarly phase Developmental therapeuticsMentors: Branimir Sikic, MD; Dmitri Colevas MDCLINICAL AND TRANSLATIONAL SCIENCE RESEARCH2016 – current A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue SarcomaRole: Principal investigatorSponsor: Eli Lilly2016 – current M15-394 A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (COMIRB 16-0263) (PRMS 16-33)Role: Principal investigatorSponsor: Abbvie2015 – current Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial SarcomaRole: Principal investigatorSponsor: Epizyme 2015 – current NCI - EAY131 - Molecular Analysis for Therapy Choice (MATCH)Role: SWOG Study Co-Chair/ChampionSponsor: ECOG-ACRIN2015 – current Medimmune – A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors who Have Received, Progressed, or are Intolerant to Standard Therapy and Have Received No More Than 3 Prior Therapies for Metastatic or Recurrent Disease.Role: Principal InvestigatorSponsor: Medimmune2015 – 2016 A091401: Phase II Study of Nivolumab with or Without Ipilimumab in Patients with Metastatic or Unresectable SarcomaRole: Principal InvestigatorSponsor: ALLIANCE2015 – current A091202 - A Phase II Randomized, Double Blinded Study Of The Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone Vs. Placebo In Patients With Previously Treated, Unresectable Myxoid LiposarcomaRole: Principal InvestigatorSponsor: ALLIANCE2015 – current ARST1321 - Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib Role: Principal Investigator/SWOG Co-Chair/ChampionSponsor: NRG 2015 – current A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Role: Principal InvestigatorSponsor: Pharmamar2015 – current A Phase 3, Randomized (1:1), Double-Blind, Placebo-Controlled, Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma (excluding Kaposi’s and GIST) which is not amenable to treatment with surgery or radiotherapy with curative intent (may have had any number of prior systemic cytotoxic therapies for advanced/metastatic disease except prior treatment with anthracyclines).Role: Principal investigatorSponsor: Eli Lilly2014 – current An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients with Advanced Soft Tissue SarcomaRole: Principal InvestigatorSponsor: Eli Lilly and Co. 2014 – currentA Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation (Chondrosarcoma)Role: Co-InvestigatorSponsor: Agios Pharmaceuticals 2014 – current A Multi-Center, Open Label, First In Human, Phase I Dose Escalation Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of RO6839921, An MDM2 Antagonist Following Intravenous Administration In Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML) Role: Co-InvestigatorSponsor: Roche2014 – currentA Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant ChemotherapyRole: Co-InvestigatorSponsor: CytRx Corporation2014 – current A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care TreatmentRole: Co-InvestigatorSponsor: Janssen Research & Development, LLC2014 – currentA Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma.Role: Co-InvestigatorSponsor: Medical University of South Carolina/GlaxoSmithKline2012 – 2014A First-in-Human Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Patients with Advanced Solid Malignancies. Role: Co-investigator; Protocol co-developer; CoauthorSponsor: Stanford University2013 – 2014A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors Role: Co-investigatorSponsor: Celldex Therapeutics NCT014601342011 – 2012 HGS1029-C1078: Phase 1 Dose Ranging Study in Patients with Advanced Solid Malignancies. Role: Co-investigatorSponsor: Human Genome SciencesNCT007080062011- 2012 OMP-21M18: A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects with Solid Tumors. Role: Co-investigatorSponsor: Oncomed PharmaceuticalsNCT007445622011 – 2012 XL-184: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors: Non-Randomized Extension. Role: Co-investigatorSponsor: ExelixisNCT009402252011 - 2013A Phase II Study of Pazopanib in Patients with Imatinib and Sunitinib Refractory or Intolerant Gastrointestinal Stroma Tumors (GIST) Role: Co-investigator; CoauthorSponsor: Glaxo-Smith-Kline/Investigator initiated NCT 013916112011 – 2014 A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, and Vincristine alternating with Irinotecan and Temozolomide in Patients with Newly Diagnosed Metastatic Ewing's SarcomaRole: Co-investigatorType of Study: Investigator initiated multi-institutional studySponsor: Amgen NCT 013138842010 - 2013A Multi-center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients with Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/diffuse-type Giant Cell TumorRole: Co-investigatorType of Study: Multi-center StudySponsor: Dana Farber Cancer Institute NCT 012074922011 – 2014 A Randomized Controlled Study of Yondelis (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma previously Treated with an Anthracycline and Ifosfamide Role: Co-investigatorType of Study: Multi-center StudySponsor: Johnson & Johnson NCT 01343277 2012 – 2014 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaRole: Co-investigatorType of Study: Multi-center StudySponsor: Threshold Pharmaceuticals NCT 01440088BASIC SCIENCE RESEARCH2011 – 2013Stanford University, Stanford, CA Elucidation of predictive biomarkers in ovarian cancer using the TCGA cancer database. I performed a fundamental reannotation of the TCGA clinical dataset in ovarian cancer. We worked closely with several bioinformaticians to include the more robust chemotherapy data to identify several novel predictive biomarkers for platinum sensitivity.Mentor: Branimir Sikic, M.D.2001 – 2007 Washington University School of Medicine, St. Louis, MOI developed novel BRET (bioluminescence resonance energy transfer) systems for imaging protease activity in living cells using new donor proteins.Mentor: David Piwnica-Worms, M.D., Ph.D. 2003 – 2008 Washington University School of Medicine, St. Louis, MO. Developed novel non-destructive multicolored protein-protein interaction sensors for use in vitro and in vivo, with the ability to monitor two discreet protein interactions simultaneously in the same cells in real-time. Mentor: David Piwnica-Worms, M.D., Ph.D. 1996 – 1999 Baylor University, Waco, TX.Synthesized novel antitumor therapeutics for optimized bioavailability and function. Among these were drugs based on combretastatin A-4, a colchicine analogue, with primary mechanism of tubulin binding and inhibition of tubulin polymerization. Mentor: Kevin Pinney, Ph.D.PUBLICATIONSVillalobos VM, Hoffner B, Elias AD. We CAN study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas. Cancer. 2016 Oct 3. doi: 10.1002/cncr.30377. Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B. Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS One. 2016 Feb 17;11(2):e0149183. Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D’Adamo D, McMillan A, Demetri GD, and George S. A Multicenter Phase II Study of Pazopanib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib. Ann Oncol 2014 25 (1): 236-240.Gevaert O, Villalobos V, Sikic BI, Plevritis S. Identification of ovarian cancer driver genes by using module network integration of multi-omics data. Interface Focus 2013 3(4): 201130013. Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, Lebensohn A, Ford JM, Telli ML. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with li-fraumeni syndrome. J Natl Compr Canc Netw. 2012 Aug 1;10(8):939-42.Villalobos VM, Naik S, Bruinsma M, Dothager RS, Pan MH, Samrakandi M, Moss B, Elhammali A, Piwnica-Worms D. Dual-color Click Beetle Luciferase heteroprotein fragment complementation assays. Chem Biol. 2010 Sep 24;17(9): 1018-29.Gammon ST*, Villalobos VM*, Roshal M, Samrakandi M, Piwnica-Worms D. Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain protease biosensors Biotechnol Prog. 2009 Mar-Apr;25(2):559-69. *Co-first authorsVillalobos VM, Naik, S, Piwnica-Worms, D. Detection of protein-protein interactions in live cells and animals with split firefly luciferase protein fragment complementation Methods Mol Biol. 2008; 439:339-52. Villalobos VM, Naik, S, Piwnica-Worms, D. Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng. 2007; 9:321-49Bullok KE, Gammon ST, Violini S, Prantner AM, Villalobos VM, Sharma V, Piwnica-Worms D. Permeation peptide conjugates for in vivo molecular imaging applications. Molecular Imaging. 2006; 5: 1-15.Piwnica-Worms, David; Luker, Kathryn E.; Villalobos, Victor M. (2005) Molecular imaging of protein-protein interactions in living animals. In: Schuster DP, Blackwell TS (Eds.), Lung Biology in Health and Disease: Molecular Imaging of the Lungs, Boca Raton, FL: Taylor & Francis Group, pp. 313-326. Gammon ST, Villalobos VM, Prior JL, Sharma V, Piwnica-Worms D. Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: Chiral and sequence-specific effects on net cell uptake. Bioconjugate Chemistry. 2003; 14: 368-76.Ferdani, Ricardo; Hu, Jiaxin; Leevy, W. Matthew; Pajewska, Jolanta; Pajewski, Robert; Villalobos, Victor; Barbour, Leonard J.; Gokel, George W. Solid-state evidence for alkali metal to arene Pi-complexation. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2001, 41: 7-12.Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.; Verdier-Pinard, P.; Hamel, E. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorganic & Medicinal Chemistry. 2000, 8, 2417-2425. ORAL PRESENTATIONS (Bolded represents national or international presentations) Desmoid tumor trial using a gamma secretase inhibitor PF-03084014: Connective Tissue Oncology Society International Meeting, Lisbon, Portugal: Nov 2016. Emerging Therapeutic Targets in Sarcoma: Cancer Center Grand Rounds, CME lecture, Grand Junction, CO: Oct 2016. A Phase II Study of a selective JAK1 Inhibitor (INCB39110) in Subjects with Advanced Sarcomas: SWOG Group Meeting, San Francisco, CA: May 2016.Emerging Targets in Sarcoma: University of Colorado, Cancer Center Symposium, Denver, CO: Mar 2016.A Patient Focused Look at Advanced Soft Tissue Sarcoma - Emerging Targets in Sarcoma: Connective Tissue Oncology Society Annual Meeting, CME lecture: Nov 2015.Jak1 Inhibitor Trial Concept for Pleomorphic and Fibrosarcomas: SWOG Group Meeting, Chicago IL: October 2015.EAY131 – NCI Match: Trial Overview: SWOG Group Meeting, Chicago IL: October 2015.Molecular Targets in Sarcoma: University of Colorado, Flint Animal Cancer Hospital, Colorado State University Veterinary School, Fort Collins, CO: July 2015.Molecular Targets in Sarcoma: University of Colorado, Developmental Therapeutics and Molecular Oncology Symposium, Denver, CO: Mar 2015.Sarcomas: Diagnosis and Management: University of Colorado Health, Cancer Center Rounds Poudre Valley Hospital, Fort Collins, CO: Feb 2015. Cytotoxic Chemotherapy: University of Colorado – Anschutz Medical Campus, Cancer Educational Series, Denver, CO: December 2014. Progress in Cancer Immunotherapy: Dana Farber Cancer Center, Cancer Seminar, Boston, MA: May 2014. Progress in Cancer Immunotherapy: University of Colorado - Anschutz Medical Campus, Cancer Seminar, Denver, CO: May 2014. Progress in Cancer Immunotherapy: University of New Mexico Cancer Center, Grand Rounds, Albuquerque, NM: February 2014. Cytotoxic Chemotherapy: Stanford University Cancer Center, Stanford Cancer Education Seminar Series, Palo Alto, CA: June 2014. Cytotoxic Chemotherapy: Stanford University Medical School, Medical school lecture, Palo Alto, CA: April 2014. Diagnosis and Treatment of Occult Primary Cancers: Stanford University Cancer Center, Stanford Cancer Education Seminar Series, Palo Alto, CA: June 2014. Targeted Therapies in Cancer: Stanford University Medical School, Medical school lecture, Palo Alto, CA: April 2014. Cytotoxic Chemotherapy Chemotherapy Administration and Pharmacology: ASCO University Faculty Presenter, Online Learning activity, CME approved: August 2013.Cytotoxic Chemotherapy: Stanford University Cancer Center, Stanford Cancer Education Seminar Series, Palo Alto, CA: June 2013. Sarcoma Clinical Cases: Multidisciplinary Management of Cancers, Invited Speaker, Palo Alto, CA, June 2013.Update on Chemotherapy for Sarcomas: Musculoskeletal Tumor Society, Annual Meeting, Invited Speaker, San Francisco, CA: June 2013.Cytotoxic Chemotherapy: Stanford University Medical School, medical school lecture, Palo Alto, CA: April 2013. Targeted Therapies in Cancer: Stanford University Medical School, Medical school lecture, Palo Alto, CA: April 2013. Cytotoxic Chemotherapy: Stanford University Cancer Center, Stanford Cancer Education Seminar Series, Palo Alto, CA: June 2012. Cytotoxic Chemotherapy: Stanford University Medical School, medical school lecture, Palo Alto, CA: May 2012. Targeted Therapies in Cancer: Stanford University Medical School, Medical school lecture, Palo Alto, CA: April 2012. POSTER PRESENTATIONSV.M. Villalobos, S. Naik, D. Piwnica-Worms. Novel luciferase complementation pairs to study protein-protein interactions in vivo. Fourth Annual Meeting of the Society for Molecular Imaging. 2005; Cologne, Germany.V.M. Villalobos, S. Naik, D. Piwnica-Worms. Novel two-color luciferase complementation systems for imaging protein-protein interactions in live cells and animals. Fifth Annual Meeting of the Society for Molecular Imaging. 2006; Kona, HawaiiWillis S, Villalobos VM, Young B, Leyland-Jones B. Frequently Deleted Genes in Ovarian Cancer as Indicators of Platinum Response. Annual Meeting of the American Society of Clinical Oncology. 2013; Chicago, IL.Villalobos VM, Wang Y, Willis S, Leyland-Jones B, Sikic BI. EIF4EBP1 exhibits a prognostic “Goldilocks” effect on ovarian cancer: a single gene biomarker for overall survival and platinum response. Annual Meeting of the American Society of Clinical Oncology. 2013; Chicago, ILVillalobos VM, Wang Y, Willis S, Leyland-Jones B, Sikic BI. EIF4EBP1 exhibits a prognostic “Goldilocks” effect on ovarian cancer: a single gene biomarker for overall survival and platinum response. Molecular Therapeutics of Cancer Research Conference 2013; Boulder, COAnsell S, Northfelt D, Flinn I, Burris H, Dinner S, Villalobos V, Sikic B, Pilja L, Yellin M, Keler T, Davis T. A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors Early Data from Ongoing Dose-Escalation in Hematologic Malignancies. Society for Immunotherapy of Cancer (SITC) Annual Meeting. 2013; National Harbor, MDInfante JR, Burris HA, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE, Pilja L, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. Annual Meeting of the American Society of Clinical Oncology. 2014; Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 3027)Ansell SM, Northfelt DW, Flinn I, Burris HA, Dinner SN, Villalobos VM, Sikic BI, Taylor MH, Pilja L, Hawthorne TR, Yellin MJ, Keler T, Davis TA. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. Annual Meeting of the American Society of Clinical Oncology. 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 3024)Mariano Pulla, Josep Tabernero, Victor Moreno, Jose Manuel Trigo Perez, Rafael Lopez, Rebecca Kristeleit, Ahmad Awada, Alexandra Leary, Jerome Alexandre, Jean-Pierre Delord, Stefano Ferrari, Armando Santoro, Emilio Bajetta, Vivek Subbiah, Steven Weitman, Victor Villalobos, Eric Raymond, Anna Sundlov, Pilar Lardelli, Sant P. Chawla. A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. ASCO Annual Meeting. 2015; Chicago, IL. Victor Villalobos, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian A. Van Tine, Chukwuemeka Okereke, Wee Teck Ng, Damien M. Cronier. A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS). AACR Annual Meeting. 2016; New Orleans, LA. Sikic B, Villalobos V et al. A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. ASCO Annual meeting. 2016; Chicago, IL. Padda SK, Shah S, Narayanan S, Colevas AD, Fisher GA, Supan D, Wakelee HA, Aoki R, Pegram MD, Villalobos VM, Liu J, Takimoto C, Chao M, Volkmer JP, Majeti R, Weissman IL, Sikic BI. A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancer. The 9th Annual Molecular Therapeutics of Cancer Research Conference, Seattle, WA, Jul 2016. Victor M. Villalobos, Stacey DaCosta, Sameer Ghate, Oluwakayode Adejoro, Jose Perez. Compliance and persistence of pazopanib in metastatic soft tissue sarcoma patients in the United States. CTOS Annual Meeting, 2016; Lisbon, Portugal.William Tap, Victor M. Villalobos, Gregory M. Cote, Howard Burris, Filip Janku, Olivier Mir, Murali Beeram, Andrew Wagner, Julia Auer, Hua Liu, Bin Wu, Katharine Yen, Sam Agresta, Shuchi S. Pandya, Jonathan Trent. A phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the chondrosarcoma dose escalation and expansion cohorts. CTOS Annual Meeting, 2016; Lisbon, Portugal.Anne Rentz, Anne Skalicky, Sameer Ghate, Sant P. Chawla, Anthony P. Conley, Victor M. Villalobos, Jose Perez. A new symptom-specific patient-reported outcome measure for patients with soft tissue sarcoma. CTOS Annual Meeting, 2016; Lisbon, Portugal.Victor M. Villalobos, Stacey DaCosta, Sameer Ghate, Oluwakayode Adejoro, Jose Perez. Real-world treatment patterns of patients with metastatic soft tissue sarcoma in the United States. CTOS Annual Meeting, 2016; Lisbon, Portugal.UNDERGRADUATE AND GRADUATE LEADERSHIP ACTIVITIES2003 – 2005 Senator in Graduate Student Senate, Washington University in St. Louis2004 – 2005 Co-chair Student Advisory Committee Washington University Division of Biologic and Biomedical Sciences2003 – 2006 Member Student Advisory Committee2004 – 2005 Chair of Faculty Mentor Awards Committee2005 – 2006 Committee for Diversity Programs 2005 – 2006 Committee for Medical Student Training Program2006 Committee for Institutional Accreditation1998 – 1999 President Baylor University Golden Wave Band (Trombone)1997 – 1998 Vice-President Baylor University Golden Wave Band1996 – 1999 Member of Kappa Kappa Psi, Music service fraternityRevised: Nov 2016 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download